Literature DB >> 11327249

Somatic and psychological features of headache in systemic lupus erythematosus.

R Omdal1, K Waterloo, W Koldingsnes, G Husby, S I Mellgren.   

Abstract

OBJECTIVE: Headaches--especially of migrainous type--have been considered part of the disease spectrum of systemic lupus erythematosus (SLE). We wished to characterize prevalence and types of headaches in SLE and find out if headache is associated with disease, personality traits, or other psychological factors.
METHODS: Fifty-eight consecutive Caucasian patients with SLE were given a clinical examination. We recorded SLE disease activity according to the SLE Disease Activity Index, types of headache according to International Headache Society criteria, and personality traits and emotional status according to Minnesota Multiphasic Personality Inventory-2 and Beck Depression Inventory (BDI).
RESULTS: Thirty-eight SLE patients (66%) were headache sufferers; of these, 22 patients (38%) had migraine and 21 (36%) had tension-type headache. Headaches were not associated with disease activity or any other disease associated variable, including tests for antiphospholipid antibodies. Migraine was associated only with a tendency to social isolation and anxiety, while tension-type headache was associated with psychological distress, such as anxiety, somatic complaints, reduced energy, mental tension, social discomfort and withdrawal, and depressive mood according to the BDI. CONCLUSION; Migraine and tension-type headaches occur frequently in patients with SLE. Migraine shows the same clinical presentation as in a non-SLE population, and may not be part of a neuropsychiatric disease spectrum. This also applies to tension-type headache, which in contrast to migraine shows some associations with emotional and personality traits, and could represent components of a chronic pain syndrome.

Entities:  

Mesh:

Year:  2001        PMID: 11327249

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Prevalence and classification of headache in patients with systemic lupus erythematosus.

Authors:  Bruno Lessa; Alex Santana; Isabella Lima; José Martônio Almeida; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

3.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

4.  H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report.

Authors:  Emanuele Tinelli; Simona Pontecorvo; Manuela Morreale; Francesca Caramia; Ada Francia
Journal:  Radiol Case Rep       Date:  2018-11-06

Review 5.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

Review 6.  Immunologic aspects of migraine: A review of literature.

Authors:  Mehrnaz Salahi; Sina Parsa; Delaram Nourmohammadi; Zahra Razmkhah; Omid Salimi; Mohammadreza Rahmani; Saeid Zivary; Monireh Askarzadeh; Mohammad Amin Tapak; Ali Vaezi; Hamidreza Sadeghsalehi; Shirin Yaghoobpoor; Mehran Mottahedi; Setareh Garousi; Niloofar Deravi
Journal:  Front Neurol       Date:  2022-09-28       Impact factor: 4.086

7.  Systemic lupus erythematosus associated with familial moyamoya disease.

Authors:  Chang Min Lee; Sang Yeob Lee; Seung Hoon Ryu; Sung Won Lee; Kyung Won Park; Won Tae Chung
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.